No Data
No Data
Kanghui Pharmaceutical's Shaanxi Production Base Renews Production License; Shares Down 6%
Shaanxi Kanghui Pharmaceutical (603139.SH): New production base passes pharmaceutical GMP compliance inspection.
On August 13th, Gelunhui reported that the newly built production base located at No. 36 YanZhi Road, Qindu District, Xianyang City passed the "pharmaceutical GMP compliance inspection" and obtained the "Drug Production License" issued by the Shaanxi Food and Drug Administration. The company's new production base passed the pharmaceutical GMP compliance inspection and obtained the "Pharmaceutical Production License", indicating that the relevant production lines of the company's new production base meet GMP requirements, which is conducive to the company's continued stable production capacity and meeting market demand. Due to the characteristics of the pharmaceutical industry,
Shareholder TBP of Shaanxi Kanghui Pharmaceutical (603139.SH) plans to transfer 10% of the company's shares to Sailexian at a price of 111 million yuan.
Shaanxi Kanghui Pharmaceutical (603139.SH) announced that on August 1, 2024, T..., a shareholder who holds more than 5% of the company's shares,...
Shaanxi Kanghui Pharmaceutical 2024 Semi-Annual Performance Forecast
Shaanxi Kanghui Pharmaceutical (603139.SH): Expected loss of 7 to 10 million yuan in the first half of the year.
On July 12th, Gelunhui announced that Shaanxi Kanghui Pharmaceutical (603139.SH) has released a performance forecast for the first half of 2024. According to preliminary calculations by the finance department, the company expects a net income attributable to the owner of the parent company of -10 million yuan to -7 million yuan in the first half of 2024, which will result in losses. The net income after deducting non-recurring gains and losses attributable to the owners of the parent company is expected to be -17.5 million yuan to -14.5 million yuan in the first half of 2024.
Shaanxi Kanghui Pharmaceutical (603139.SH): Received a performance compensation of 2 million yuan.
On June 11th, Gelunhui reported that Shaanxi Kanghui Pharmaceutical (603139.SH) has received the first performance compensation of 2 million yuan from Hongfu Medicine on the date of this announcement. Lansheng has not yet fully fulfilled its performance commitment compensation obligation.
No Data